Ardelyx (ARDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended September 2025, Ardelyx (ARDX) reported revenue of $110.33 million, up 12.3% over the same period last year. EPS came in at $0, compared to $0 in the year-ago quarter.The reported revenue represents a surprise of +10.52% over the Zacks Consensus Estimate of $99.83 million. With the consensus EPS estimate being -$0.06, the EPS surprise was +100%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Ardelyx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues- Product sales, net: $105.52 million versus $97.49 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +14.6% change.Product sales- IBSRELA: $78.16 million versus $70.88 million estimated by five analysts on average.Product sales- XPHOZAH: $27.36 million versus the five-analyst average estimate of $26.61 million.Revenues- Licensing: $0.03 million versus $0.18 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +25% change.Non-cash royalty revenue related to the sale of future royalties: $4.79 million versus the two-analyst average estimate of $1.29 million. The reported number represents a year-over-year change of +492%.View all Key Company Metrics for Ardelyx here>>>Shares of Ardelyx have returned -7.5% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ardelyx, Inc. (ARDX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks